The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL. A step by step approach combining orthogonal measurements with increasing complexity
Open accessAbstract
The particle size distribution (PSD) and the stability of nanoparticles enabled medicinal products (NEP) in complex biological environments are key attributes to assess their quality, safety and efficacy. Despite its low resolution, dynamic light scattering (DLS) is the most common sizing technique since the onset of NEP in pharmaceutical technologies. Considering the limitations of the existing sizing measurements and the challenges posed by complex NEPs both scientists and regulators encourage the combination of multiple orthogonal high-resolution approaches to shed light in the NEP sizing space (e.g. dynamic light scattering, electron microscopy, field flow fractionation coupled to online sizing detectors, centrifugal techniques, particle tracking analysis and tunable resistive pulse sensing). The pharmaceutical and biotechnology developers are now challenged to find their own pragmatic characterisation approaches, which should be fit for purpose and minimize costs at the same time, in a complicated landscape where only a few standards exist. In order to support the community, the European Nanomedicine Characterisation Laboratory (EUNCL) and the US National Cancer Institute Nanotechnology Characterization Laboratory (NCI-NCL) have jointly developed multiple standard operating procedures (SOPs) for NEP assessment, including the measurements of particle size distribution, and are offering wide access to their 'state of the art' characterisation platforms, in addition to making SOPs publicly available. This joint perspective article would like to present the NCI-NCL and EUNCL multi-step approach of incremental complexity to measure particle size distribution and size stability of NEPs, consisting of a quick preliminary step to assess sample integrity and stability by low resolution techniques (pre-screening), followed by the combination of complementary high resolution sizing measurements performed both in simple buffers and in complex biological media. Test cases are presented to demonstrate: i) the need for employing at least one high-resolution sizing technique, ii) the importance of selecting the correct sizing techniques for the purpose, and iii) the robustness of utilizing orthogonal sizing techniques to study the physical properties of complex NEP samples.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Particle size-dependent organ distribution of gold nanoparticles after intravenous administration
De Jong, W. H., Hagens, W. I., Krystek, P., Burger, M. C., Sips, A. J. A. M., & Geertsma, R. E. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.12.037 · Cited by 1,615
Physical approaches to biomaterial design
Mitragotri, S., & Lahann, J. (2009) · Nature Materials · doi:10.1038/nmat2344 · Cited by 1,445
Maguire, C. M., Rösslein, M., Wick, P., & Prina-Mello, A. (2018) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2018.1517587 · Cited by 387
Self-citationKuntsche, J., Horst, J. C., & Bunjes, H. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.02.001 · Cited by 363
Characterization of Nanoparticles Intended for Drug Delivery
(2011) · Methods in Molecular Biology · doi:10.1007/978-1-60327-198-1 · Cited by 358
The evolving landscape of drug products containing nanomaterials in the United States
D'Mello, S. R., Cruz, C. N., Chen, M.-L., Kapoor, M., Lee, S. L., & Tyner, K. M. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.67 · Cited by 345
Klang, V., Matsko, N. B., Valenta, C., & Hofer, F. (2012) · Micron · doi:10.1016/j.micron.2011.07.014 · Cited by 329
Crist, R. M., Grossman, J. H., Patri, A. K., Stern, S. T., Dobrovolskaia, M. A., Adiseshaiah, P. P., Clogston, J. D., & McNeil, S. E. (2013) · Integrative Biology · doi:10.1039/c2ib20117h · Cited by 265
Self-citationOn the issue of transparency and reproducibility in nanomedicine
Leong, H. S., Butler, K. S., Brinker, C. J., Azzawi, M., Conlan, S., Dufés, C., Owen, A., Rannard, S., Scott, C., Chen, C., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0496-9 · Cited by 242
Self-citationFranken, L. E., Boekema, E. J., & Stuart, M. C. A. (2017) · Advanced Science · doi:10.1002/advs.201600476 · Cited by 207
Analytical ultracentrifugation of colloids
Planken, K. L., & Cölfen, H. (2010) · Nanoscale · doi:10.1039/c0nr00215a · Cited by 172
Rice, S. B., Chan, C., Brown, S. C., Eschbach, P., Han, L., Ensor, D. S., Stefaniak, A. B., Bonevich, J., Vladár, A. E., Walker, A. R. H., et al. (2013) · Metrologia · doi:10.1088/0026-1394/50/6/663 · Cited by 168
Nanotechnology in Cancer Medicine
Grossman, J. H., & McNeil, S. E. (2012) · Physics Today · doi:10.1063/pt.3.1678 · Cited by 157
Mapping of the available standards against the regulatory needs for nanomedicines
Halamoda‐Kenzaoui, B., Holzwarth, U., Roebben, G., Bogni, A., & Bremer‐Hoffmann, S. (2018) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1531 · Cited by 157
Yohannes, G., Jussila, M., Hartonen, K. M., & Riekkola, M. (2011) · Journal of Chromatography A · doi:10.1016/j.chroma.2010.12.110 · Cited by 156
Measuring nanoparticles size distribution in food and consumer products: a review
Calzolai, L., Gilliland, D. D., & Rossi, F. (2012) · Food Additives & Contaminants Part A · doi:10.1080/19440049.2012.689777 · Cited by 145
Self-citationAsymmetric Flow Field-Flow Fractionation in the Field of Nanomedicine
Wagner, M., Holzschuh, S., Traeger, A., Fahr, A., & Schubert, U. S. (2014) · Analytical Chemistry · doi:10.1021/ac501664t · Cited by 141
Field flow fractionation techniques to explore the “nano-world”
Contado, C. (2017) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-017-0180-6 · Cited by 137
Are Existing Standard Methods Suitable for the Evaluation of Nanomedicines: Some Case Studies
Gioria, S., Caputo, F., Urbán, P., Maguire, C. M., Bremer‐Hoffmann, S., Prina‐Mello, A., Calzolai, L., & Méhn, D. (2018) · Nanomedicine · doi:10.2217/nnm-2017-0338 · Cited by 137
Self-citationApplications of tunable resistive pulse sensing
Weatherall, E., & Willmott, G. R. (2015) · The Analyst · doi:10.1039/c4an02270j · Cited by 135
Basic Principles of Analytical Ultracentrifugation
Schuck, P., Zhao, H., Brautigam, C. A., & Ghirlando, R. (2015) · CRC Press eBooks · doi:10.1201/b19028 · Cited by 129
Electron microscopy of pharmaceutical systems
Klang, V., Valenta, C., & Matsko, N. B. (2012) · Micron · doi:10.1016/j.micron.2012.07.008 · Cited by 125
Cryo‐electron microscopy and cryo‐electron tomography of nanoparticles
Stewart, P. L. (2016) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1417 · Cited by 122
Coty, J.-B., & Vauthier, C. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.013 · Cited by 121
Varenne, F., Makky, A., Gaucher, M., Violleau, F., & Vauthier, C. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1867-7 · Cited by 112
Separation and characterization of gold nanoparticle mixtures by flow-field-flow fractionation
Calzolai, L., Gilliland, D. D., García, C. P., & Rossi, F. (2011) · Journal of Chromatography A · doi:10.1016/j.chroma.2011.01.017 · Cited by 108
Self-citationIdentification of regulatory needs for nanomedicines
Bremer‐Hoffmann, S., Halamoda‐Kenzaoui, B., & Borgos, S. E. (2018) · Journal of Interdisciplinary Nanomedicine · doi:10.1002/jin2.34 · Cited by 106
Quantitative characterization of nanoparticle agglomeration within biological media
Hondow, N., Brydson, R., Wang, P., Holton, M. D., Brown, M. R., Rees, P. C. T., Summers, H. D., & Brown, A. (2012) · Journal of Nanoparticle Research · doi:10.1007/s11051-012-0977-3 · Cited by 104
Flow field-flow fractionation for the analysis of nanoparticles used in drug delivery
Zattoni, A., Roda, B., Borghi, F., Marassi, V., & Reschiglian, P. (2013) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2013.08.018 · Cited by 102
Caputo, F., Arnould, A., Bacia‐Verloop, M., Ling, W. L., Rustique, E., Texier, I., Prina‐Mello, A., & Couffin, A. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01033 · Cited by 98
Self-citationPauw, B. R., Kästner, C., & Thünemann, A. F. (2017) · Journal of Applied Crystallography · doi:10.1107/s160057671701010x · Cited by 87
Analytical ultracentrifugation for analysis of doxorubicin loaded liposomes
Méhn, D., Iavicoli, P., Cabaleiro, N., Borgos, S. E., Caputo, F., Geiss, O., Calzolai, L., Rossi, F., & Gilliland, D. D. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.03.046 · Cited by 77
Self-citationParot, J., Caputo, F., Méhn, D., Hackley, V. A., & Calzolai, L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.049 · Cited by 77
Self-citationMaguire, R., Hanly, P. A., & Maguire, P. (2019) · Quality of Life Research · doi:10.1007/s11136-019-02122-y · Cited by 67
Larger or more? Nanoparticle characterisation methods for recognition of dimers
Méhn, D., Caputo, F., Rösslein, M., Calzolai, L., Saint-Antonin, F., Courant, T., Wick, P., & Gilliland, D. D. (2017) · RSC Advances · doi:10.1039/c7ra02432k · Cited by 58
Self-citationDetermination of the structure and morphology of gold nanoparticle–HSA protein complexes
Capomaccio, R. B., Ojea‐Jiménez, I., Colpo, P., Gilliland, D. D., Ceccone, G., Rossi, F., & Calzolai, L. (2015) · Nanoscale · doi:10.1039/c5nr05147a · Cited by 55
Self-citationWhen Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?
Stern, S. T., Martinez, M. N., & Stevens, D. M. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.073148 · Cited by 47
Stable isotope method to measure drug release from nanomedicines
Skoczen, S., McNeil, S. E., & Stern, S. T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.042 · Cited by 45
Early Development Challenges for Drug Products Containing Nanomaterials
Grossman, J. H., Crist, R. M., & Clogston, J. D. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9980-4 · Cited by 38
Self-citationBitounis, D., Pyrgiotakis, G., Bousfield, D. W., & Demokritou, P. (2019) · NanoImpact · doi:10.1016/j.impact.2019.100171 · Cited by 32
Méhn, D., Rio-Echevarria, I. M., Gilliland, D. D., Kaiser, M., Vilsmeier, K., Schuck, P., & Wohlleben, W. (2017) · NanoImpact · doi:10.1016/j.impact.2017.12.005 · Cited by 25
Sedimentation Velocity Analytical Ultracentrifugation
Schuck, P., & Zhao, H. (2017) · CRC Press eBooks · doi:10.1201/b21988 · Cited by 22
Hansen, M., Smith, M. C., Crist, R. M., et al. (2015) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-015-9056-9 · Cited by 18
Cited by
Takahashi, K., & Sakurai, K. (2020) · Drug Delivery System · doi:10.2745/dds.35.332 · Cited by 917
Current hurdles to the translation of nanomedicines from bench to the clinic
Đorđević, S., Gonzalez, M. M., Conejos-Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi-Fainaro, R., Florindo, H. F., & Vicent, M. J. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01024-2 · Cited by 657
Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors
Gagliardi, A., Giuliano, E., Venkateswararao, E., Fresta, M., Bulotta, S., Awasthi, V., & Cosco, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.601626 · Cited by 571
Analytical characterization of liposomes and other lipid nanoparticles for drug delivery
Fan, Y., Marioli, M., & Zhang, K. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113642 · Cited by 395
Liposomes as biocompatible and smart delivery systems – the current state
Dymek, M., & Sikora, E. (2022) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2022.102757 · Cited by 392
Metadata
- Authors
- Caputo, F., Clogston, J., Calzolai, L., Rösslein, M., & Prina-Mello, A.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 299
- Pages
- 31-43
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2918110300
- Cited by
- 337
- References
- 44
- FWCI
- 9.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.